Fairvalue-Calculator Fairvalue-Calculator
EN DE

Fujian Aonong Biological Technology Group (603363) Fair Value & Analysis

Consumer Defensive · CN · Market cap 7.9B CNY

Price¥2.74
Fair Value¥0.5000
Upside-81.8%
Quality87/100
Evidence: Medium Range ¥0.4500 – ¥0.7000

Analysis

Fujian Aonong Biological Technology Group (603363) currently trades at ¥2.74, while our model-based Fair Value estimate is ¥0.5000 — implying the stock looks roughly 81.8% overvalued today. We read business quality at 87/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Fujian Aonong Biological Technology Group Incorporation Limited engages in the feed, pig farming, food, supply chain services, and other businesses in China and internationally. It researches and develops, produces, and sells feed products, such as pig feed, poultry feed, aquatic feed, ruminant feed, and other products; operates pig breeding farms; and engages in the pig slaughtering and processing activities, as well as raw materials trade. The company offers feed, live pigs, pork and meat products, as well as creates pig OK management platform. Fujian Aonong Biological Technology Group was founded in 2011 and is based in Zhangzhou, China.

Open the full interactive analysis →

Similar stocks

Archer-Daniels-Midland Company (ADM) -53% MHP SE (MHPC) -88% Muyuan Foods Group (002714) +40% Bunge Global SA (BG) -31% Tyson Foods, Inc (TSN) -17% Wens Foodstuff Group (300498) -3%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.